Results 11 to 20 of about 662,207 (147)
Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy [PDF]
Cardiovascular Diabetology, 2023 Recent type 2 diabetes guidance from the UK’s National Institute for Health and Care Excellence (NICE) proposes offering SGLT2-inhibitor therapy to people with established atherosclerotic cardiovascular disease (ASCVD) or heart failure, and considering ...
Katherine G. Young +6 more
doaj +9 more sources
Lipids in Health and Disease, 2017 Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile in patients with type 2 diabetes.
Seon-Ah Cha +7 more
doaj +2 more sources
Is GFR decline induced by SGLT2 inhibitor of clinical importance? [PDF]
Cardiovascular DiabetologyBackground Use of sodium-glucose-cotransporter-2 (SGLT2) inhibitors often causes an initial decline in glomerular filtration rate (GFR). This study addresses the question whether the initial decline of renal function with SGLT2 inhibitor treatment is ...
Merve Günes-Altan +6 more
doaj +2 more sources
BMJ Open Diabetes Research & CareIntroduction Recent post hoc analyses indicate that patients with normal or low body mass index (BMI) benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitor use. We aimed to evaluate the effects of SGLT2 inhibitors on renal and patient outcomes in
Hye Ryoun Jang +6 more
doaj +2 more sources
, 2014 SGLT2 inhibition in diabetic ...
Muralikrishna Gangadharan komala (595016)
core +3 more sources
Cell Death and Disease, 2022 SGLT2 (sodium-glucose cotransporter 2) is an important mediator of epithelial glucose transport and has been reported that SGLT2, robustly and diffusely expressed in malignant cancer cells, was overexpressed in various tumors, and inhibiting the SGLT2 ...
Wei Wu +6 more
doaj +1 more source
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD [PDF]
, 2023 Rationale & objective: Sodium/glucose cotransporter 2 (SGLT2) inhibitors are recommended for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or atherosclerotic cardiovascular disease (ASCVD).
L. Parker Gregg +14 more
core +1 more source
An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus [PDF]
, 2012 Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. The kidney emerges out as
Manju Sharma +4 more
core +1 more source
Journal of Diabetes Investigation, 2022 Aims/Introduction We evaluated the effect of co‐administration of esaxerenone and a sodium–glucose cotransporter 2 (SGLT2) inhibitor on the magnitude of serum potassium elevation in Japanese patients with diabetic kidney disease. Materials and Methods We
Kenichi Shikata +7 more
doaj +1 more source
Possible renoprotective mechanisms of SGLT2 inhibitors
Frontiers in Medicine, 2023 Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor in patients with chronic kidney disease reduces the renal risk independent of changes in blood glucose concentrations and blood pressure.
Akira Nishiyama, Kento Kitada
doaj +1 more source